Christos Fountzilas

Associate Professor

Roswell Park Comprehensive Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Research Cancer Research professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Christos Fountzilas is an Associate Professor at Roswell Park Comprehensive Cancer Center in the United States. His research focuses on advanced solid tumors, colorectal cancer, and pancreatic cancer, as evidenced by his recent publications on combination therapies and biomarker studies. He is involved in investigating therapeutic strategies for various cancer types, highlighting the implications of genetic factors in cancer treatment.

Articles (10)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Thomas Melendy

University at Buffalo

UNITED STATES

View details

Kevin Eng

Research Assistant Professor

State University of New York at Buffalo

UNITED STATES

View details

Andrew Goey

Assistant Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christos Fountzilas

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair

A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors

A phase II study of TAS-102, irinotecan, and bevacizumab in pretreated metastatic colorectal cancer (TABAsCO)

Cruciferous vegetable consumption and pancreatic cancer: A case-control study

Pancreatic adenocarcinoma, Version 2.2021

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature

A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma

Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors

Mutant kras as a biomarker plays a favorable role in fl118-induced apoptosis, reactive oxygen species (Ros) production and modulation of survivin, mcl-1 and xiap in human bladder cancer

Collaborators (3)

Thomas Melendy

Kevin Eng

Andrew Goey

Make your next move.